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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by inflammation and remodeling of
the lungs. This results in alterations in extracellular matrix (ECM) and structural changes leading to airflow
obstruction. We studied the expression of tenascin-C (Tn-C) and alpha smooth muscle actin (a-SMA), which act as
a marker of myofibroblasts, in large airways from COPD patients. Our aim was to elucidate whether this expression
correlated with smoking or with disease development.
Methods: Bronchoscopy was performed on 20 COPD patients (mean age 56 years; range 39-61; FEV1/FVC < 70%
and FEV1 median 53% (range 33-69) of predicted). Age and smoking matched smokers (S) without COPD (n = 13)
and age matched non-smokers (NS) (n = 14) served as controls. Bronchial mucosal biopsies were analyzed by
immunohistochemistry. The distribution of Tn-C expression was assessed and graded in three levels, and the
number of spindle shaped cells staining positive for a-SMA were counted.
Results: Biopsies from COPD patients had more (P < 0.001) Tn-C expression than the two control groups. A
significantly (P < 0.05) increased number of spindle shaped cells expressing a-SMA was observed in COPD patients
compared with the controls. Smokers and nonsmokers did not differ in this respect. The expression of Tn-C
correlated positively (P < 0.001) to the number of a-SMA positive cells.
Conclusions: We demonstrate increased expression of Tn-C and a-SMA positive cells in the large airways in COPD.
This was not associated to smoking per se, but to the presence of airway obstruction. Our findings add new
information regarding remodeling characteristics and highlight the large airways as a potential site for airways
obstruction in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is
recognized as an important cause of morbidity and mor-
tality [1], affecting 7-14% of all adults in the western
world [2,3]. Tobacco smoking is identified as the most
important risk factor, and the disease is associated with
an abnormal inflammatory response in the lung [4].
Inflammation in COPD has been displayed at different
levels within the bronchial three and in the lung par-
enchyma [5-7]. This inflammatory response is chronic
in nature and has been associated with an increased
level of profibrotic mediators such as transforming
growth factor b (TGF-b) and epidermal growth factor
(EGF) [8]. The major site of the airways obstruction in
COPD is located in the small airways and the obstruc-
tion per se has been found to be associated with struc-
tural changes in the bronchioles and in the pulmonary
parenchyma [9]. Fibrosis observed in the subepithelial
region in the large airways is a hallmark of asthma [10]
and has been shown to correlate to disease severity
[11-13]. In COPD or in chronic bronchitis, some studies
have shown no alteration in reticular basement thick-
ness [14] whereas other studies have shown a thickening
of the reticular basement membrane compared to con-
trols [11,15].
Tenascin-C (Tn-C) is an extracellular matrix glycopro-
tein involved in tissue remodeling. Its expression is
increased in the airway wall in diseases characterized by
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has been shown to be increased in a number of other
lung diseases associated with remodelling of extracellu-
lar matrix (ECM), such as idiopathic pulmonary fibrosis
(IPF), allergic alveolitis, sarcoidosis, asbestosis, crypto-
genic organizing pneumonia (COP), tuberculosis, atypi-
cal mycobacteriosis, lung cancer, mesothelioma and
inflammatory myofibroblastic tumor [18-20], Tn-C has
also been reported to be expressed, during fetal develop-
ment of the human lung [21] but not in healthy human
adult lung. In many lung diseases but also during lung
development, a-smooth muscle positive cells (a-SMA),
which were obviously myofibroblasts, were shown to pro-
duce most of the Tn-C mRNA [22,23]. Myofibroblasts
are fibroblast-like cells that were discovered in the early
70’s [24]. These cells were initially defined in ultrastruc-
tural terms, with the essential features being stress fibers,
well-developed cell-to-stroma attachment sites i.e. fibro-
nexus and intercellular intermediate and gap junctions
[25]. Microscopic studies demonstrated that these cells
express aalpha-SMA, fibronectin and vimentin [26].
Nowadays myofibroblasts are supposed to be the elemen-
tary factors in the pathogenesis of IPF and cancers [27].
aalpha-SMA is the most commonly used marker for a
myofibroblast, although not specific, since also smooth
muscle and endothelial cells express this marker [28].
Vimentin is an intermediate filament which is virtually
always present in mesenchymal cell lines or neoplasms.
At the present, the ubiquity of vimentin in soft tissues
limits its diagnostic use in differentiating cell types and it
mostly serves as a positive specimen control [29]. Vimen-
tin is also expressed in inflammatory cells [30].
Studies on Tn-C expression from patients with COPD
are sparse whereas other ECM proteins have been more
extensively analyzed. Krakenberg and co-authors
observed that fibronectin, collagens I, III and IV, lami-
nin and hyaluronan were enhanced in lung tissues of
COPD-patients [31]. On the other hand, a recent study
by Gosselink et al revealed that fibronectin is decreased
in small airways of COPD patients [32]. A previous
experimental study using primary human lung fibro-
blasts cultured from patients with COPD and asthma
showed that fluticasone propionate increased the expres-
sion of fibronectin but decreased the expression of Tn-C
whereas salmeterol neither affected fibronectin or Tn-C
[33]. In our own recently published study precursors of
collagen I and III were shown to have variable expres-
sion profiles in large and small airways of the patients
with different stages of COPD [34].
Given the chronic nature of inflammation in COPD
and the importance of structural changes for lung func-
tion impairment [35], our aim was to quantify measures
of remodeling in the large airways in COPD compared
to smokers and nonsmokers. We therefore hypothesized
that the expression of Tn-C is increased in COPD simi-
larly to many other ECM proteins. Moreover, we wanted
to analyze if the number of a-SMA positive cells, which
probable represent myofibroblasts, are increased in
COPD. Cell-specific expression of Tn-C and a-SMA
was analyzed in whole bronchial biopsy tissue area, not
only in the area of the basement membrane, and the
immunohistochemical findings were correlated with the
clinical data of the patients.
Materials and methods
Patients and control subjects
Twenty patients with COPD, aged 39-61 years (mean
age 57) were recruited from the Division of Respiratory
Medicine, Karolinska University Hospital Solna, Stock-
holm, Sweden (Table 1). All patients had a post bronch-
odilator FEV1/VC<70% and FEV1<70% of predicted and
a smoking history of more than ten pack-years. In the
COPD group, three of the patients had quit smoking.
These three ex-smokers had a post bronchodilator FEV1
of 1.06, 2.17 and 1.65 (L), and had quit, respectively,
nine years, six months and ten years prior to the study
entrance. None of the patients in the COPD group had
clinical history or radiological signs of any other pul-
monary disease than COPD. Age-matched smokers (n =
13) without COPD and non-smokers (n = 14) served as
controls. The COPD patients and the control group of
Table 1 Characteristics and lung function data in COPD
patients, smoking controls (S) and non-smoking
controls (NS)
COPD S NS
N (n) 20 13 14
Males (n) 11 6 7
Age (years) 56 ± 5 55 ± 7 57 ± 4
Pack-years (years) 34 (24-43)### 36 (27-37)††† 0
FEV1/FVC 0.54
(0.38-0.52)
***###
0.80 (0.76-
0.81)
0.84 (0.83-
0.84)
FEV1/VC 0.48
(0.52-0.62)
***###
0.79 (0.75-
0.83)
0.77 (0.76-
0.80)
FEV1 (L) 1.58
(1.22-1.94)
***###
2.89 (2.71-
3.57)
3.32 (2.75-
3.94)
FEV1 (% predicted) 53 (47-60)***### 98 (95-104)† 109 (106-121)
FEV1 reversibility (%) 14 (4-19)***### 4 (0-5) 2 (0-3)
FEV1 reversibility
(mL)
190 (75-265)# 90 (0-170) 70 (8-105)
Data are shown as mean and standard deviation for age, mean and inter
quartile range for pack-years, median and inter quartile range for all others.
Significant difference between groups is marked with * (COPD vs HS), #
(COPD vs NS) and † (HS vs NS). The considered levels of significance were P <
0.05 (*, # or †), P < 0.01 (**, ## or ††) and P < 0.001 (***, ### or †††). FEV1:
Forced expiratory volume in one second, measured post bronchodilation; FVC:
Forced vital capacity; VC: Vital capacity.
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assessed as pack-years. All had a normal chest X-ray.
No patient or control subject had a history suggesting
allergy or asthma. All patients and controls were in a
stable condition (i.e. none had a respiratory tract infec-
tion within three months prior to the study), and no
participant had received oral or inhaled corticosteroids
during the three months preceding the inclusion. Nine
of the COPD patients used bronchodilator inhalers.
Four of them had a short-acting beta-agonist inhaler,
three had long-acting beta-agonist inhaler and two had
a short-acting antimuscarinic inhaler. In addition, six
patients used oral N-acetylcysteine.
Each participant gave an informed consent and the
study had the approval from the regional ethics commit-
tee, Karolinska University Hospital, Stockholm, Sweden,
approval number: 99-319.
Pulmonary function test
All participants performed a dynamic spirometry in a
standardized manner (Vitalograph
®, Buckingham, UK).
Both slow vital capacity and forced vital capacity was
performed, before and 10 minutes after inhalation with
2 doses of 0.5 mg terbutalin (Bricanyl
® Turbuhaler
®;
AstraZeneca, Södertälje, Sweden), and reversibility was
calculated.
Bronchoscopy and bronchial biopsies
Bronchoscopy was performed as described previously
[36]. Biopsy specimens were taken by use of pulmonary
biopsy forceps with smooth edge jaws (Radial Edge
®
Biopsy Forceps, Boston Scientific, Boston, MA). Four to
six endobronchial mucosal biopsies were taken from
each subject, and they were all collected from lobar or
segmental carinae of the upper left lobe or the apical
segment of the lower left lobe.
Processing and immunohistochemical stainings of
bronchial biopsies
All biopsies were immediately formalin-fixed and
embedded in paraffin. The material was evaluated, and
representative tissue blocks from each case were
selected for immunohistochemistry studies. Immunohis-
tochemical stainings were performed as described pre-
viously [20,22,23,35,37,38]. Negative controls were
obtained by using non-immune serum and PBS as sub-
stitute for the primary antibodies. Information of the
antibodies used is shown in Table 2.
Quantification of Tn-C and a-SMA expression
Two experienced pulmonary pathologists (RK and ELB)
evaluated all biopsies. When analyzing the lung samples,
both pathologists were blinded to the disease group sta-
tus of the patients. 1-4 biopsy samples of each patient
were analyzed, but for the statistics only one sample of
each case was selected. The average area of the sections
was 1-2 mm
2, and the whole tissue section was analyzed
by immunohistochemistry in each case. Immunohisto-
chemical stainings for Tn-C and a-SMA was performed
in serial sections, i.e. in consecutive sections. Staining
for desmin was done in 44 of the most representative
cases for phenotyping the a-SMA positive cells. In addi-
tion, vimentin was evaluated in 22 cases in which the
tissue material was available.
The quantitative expression of Tn-C was assessed in
three categories. Tn-C (a): staining present in basal
epithelial cells and basement membrane of the bronchial
epithelium; Tn-C (b): staining present as in Tn-C (a)
and in the stroma underneath the basement membrane;
Tn-C (c):s t a i n i n gp r e s e n ta si nTn-C (b) and in the
wider area of the connective tissue of bronchial walls.
Representative microphotographs for Tn-C are displayed
in Figure 1A-C.
The expression of a-SMA was assessed in spindle
shaped cells which were obvious myofibroblasts. Smooth
muscle cells and cells of vessels were not scored. Quan-
tification of the staining was assessed in four categories.
SMA (a):n oc e l l s ;SMA (b): 1-4 cells; SMA (c): 5-10;
SMA (d): >10 cells stained for a-SMA. See Figure 1D-F
for representative microphotographs of the expression
of a-SMA.
Statistical analysis
Descriptive data on the study population were analyzed
by Kruskal-Wallis ANOVA and median test for differ-
ences between the three groups and by Mann-Whitney
test for comparison between two groups.
To analyse differences on immunohistochemistry
between the groups, we employed a proportional odds
analysis for categorical data. For Tn-C, the two odds
ratios Tn-C (a) vs. Tn-C (b+c) and Tn-C (a+b) vs. Tn-
C( c )were assumed to be the same within the pair
wise comparison between the groups. For a-SMA
expression, the three odds ratios SMA (a) vs. SMA (b
+c+d), SMA (a+b) vs. SMA (c+d) and SMA (a+b+c) vs.
SMA (d) were assumed to be the same within the pair
wise comparison between the groups. The proportional
odds model fits data well as demonstrated by the
Table 2 List of the antibodies, concentrations and
antigen-retrieval methods used in the study
Antibody Source Concentration Antigen retrieval
a-SMA Dako 1:1000 MW 19 min in tris-EDTA‡
Desmin Dako 1:300 MW 19 min in tris-EDTA
Tn-C Biohit 1:1000 MW 30 min in tris-EDTA
Vimentin Dako 1:1500 MW 14 min in citrate†
MW = microwave heat treatment; ‡ = tris/EDTA buffer, pH 9.0; † = citrate
buffer, pH 6.0
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Page 3 of 11Figure 1 The immunohistochemical expression of Tn-C (1 A-C) and a-SMA (1 D-F) in bronchial biopsies from study subjects.T h e
figures show representative microphotographs from each category. A: Positivity for Tn-C is seen in tangentially sectioned basal epithelial cells
and along the basement membrane (BM) of bronchial epithelium (arrows); scale bar = 0.05 mm. B: Tn-C positivity in basal epithelial cells and in
the stroma underneath the BM (arrows); scale bar = 0.05 mm. C: Positivity for Tn-C in basal epithelial cells and in a wide area of stromal
connective tissue underneath the BM (arrows); scale bar = 0.05 mm. D: Spindle shaped cells positive for a-SMA (arrows) in a biopsy graded to
the category 1-4 positive cells. Smooth muscle of the bronchial wall (SM) or blood vessels (arrow heads) were not counted; scale bar = 0.05 mm.
E: A bronchial biopsy graded to the category 5-10 a-SMA positive cells (arrows). Blood vessels (arrow heads) or smooth muscle layer of the
bronchial wall (SM) were not counted; scale bar = 0.05 mm. F: More than 10 spindle shaped cells are showing positivity for a-SMA (arrows) in a
bronchial biopsy; scale bar = 0.05 mm.
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for homogeneity, i.e. no difference between all three
groups, was statistically significant for both Tn-C (p =
0.003) and a-SMA (p = 0.039), but since the difference
between the HS and NS groups was small, we
expressed the main effect by comparing the COPD
group to HS and NS combined (geometric mean of the
odds). Correlations between Tn-C and a-SMA expres-
sion and lung function were calculated with Spear-
man’s rank correlation coefficient.
A significance level of 5% was applied for all statistical
tests, and in case of a statistically significant result the
probability value (p-value) is given.
Results
Immunohistochemistry for Tn-C
In general, Tn-C was expressed as extracellular thin and
linear fibers underneath the bronchial epithelium and
also in the wider area of connective tissue of the bron-
chial walls. All evaluated biopsies showed positivity for
Tn-C also in basal epithelial cells but the expression pro-
file varied considerable between different patients. Repre-
sentative microphotographs are shown in Figure 1A-C.
The number and proportion of subjects within each
staining category are presented in Table 3 and Figure 2.
As shown, both the numbers of patients and the propor-
tion of subjects expressing Tn-C staining beyond basal
epithelial cells and basal membrane, was higher in COPD
patients compared to smokers and nonsmokers (P <
0.001). Of the three ex-smokers in the COPD group, two
were in the lowest staining category (a),a n do n ei nt h e
intermediate (b).
Immunohistochemistry for a-SMA
Spindle shaped a-SMA positive cells were present in a
proportion of subjects from all three study groups,
representative microphotographs are shown in
Figure 1D-F and Figure 3A. Out of the 44 cases with
available stainings for desmin, 17 cases were spindle
shaped cells positive both for a-SMA and desmin,
and 15 cases were spindle shaped cells positive for a-
SMA but negative for desmin. In the remaining 12
cases no spindle shaped cells positive for either a-
SMA or desmin were found which finding indicate
that those cases did not revealed any myofibroblasts.
In the cases with spindle shaped cells positive for
both antibodies, the desmin positive cells were always
very few in numbers (Figure 3B). The a-SMA positive
smooth muscle cells and endothelial cells were
excluded by their different location and morphology
when compared to that of spindle shaped cells (Figure
3C-D).
The number and proportion of subjects within each
staining category are presented in Table 3 and Figure 4.
Presence of a-SMA staining was observed in 83% of the
COPD patients, in 46% of the smokers and in 41% of
the nonsmokers. When data are presented as cumulative
number and proportion of individuals with increasing
number of cells stained positive for a-SMA, COPD
patients had significantly higher (P < 0.05) a-SMA
expression than smokers and nonsmokers.
Of the three ex-smokers in the COPD group, one was
in category (b), and two were in category (c).
Immunohistochemistry for vimentin
Regardless of the presence of a-SMA or desmin positive
spindle shaped cell, all cases expressed vimentin positive
slender stromal cells. Most of them were probably fibro-
blasts of the subepithelial connective tissue (Figure 2E).
In addition to this, all inflammatory cells stained posi-
tively for vimentin.
Correlation between Tn-C and a-SMA
The expression of Tn-C correlated positively to the
expression of a-SMA. The estimate for the correlation
coefficient was 0.6; P < 0.0001 (Figure 5).
Table 3 The expression of Tenascin-C and a-SMA in patients with COPD, smokers (S) and non-smokers (NS)
COPD S NS
Tenascin C (Tn-C)
Number of acceptable biopsies 20 12 14
Subjects expressing Tn-C only in basal epithelial cells and basal membrane, Tn-C (a) 5( 25%)9 ( 75%)1 1 ( 79%)
Subjects expressing Tn-C as Tn-C (a) plus the stroma underneath basement membrane, Tn-C (b) 10 (50%)2 ( 17%)3 ( 21%)
Subjects expressing Tn-C as Tn-C (b) plus wider expression within connective tissue, Tn-C (c) 5( 25%)1 ( 8%)0 ( 0%)
a-SMA
Number of acceptable biopsies 18 13 12
Subjects with no cells expressing a-SMA, SMA (a) 3( 17%)7 ( 54%)7 ( 59%)
Subjects with 1-5 cells expressing a-SMA, SMA (b) 6( 33%)2 ( 15%)3 ( 25%)
Subjects with 5-10 cells expressing a-SMA, SMA
© 4( 22%)3 ( 23%)1 ( 8%)
Subjects with >10 cells expressing a-SMA, SMA (d) 5( 28%)1 ( 8%)1 ( 8%)
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lung function parameters
There was no correlation between the expression of Tn-
Co ra-SMA and any parameter of pulmonary function
(data not shown).
Discussion
In this study, we investigated by immunohistochemistry
the expression of Tn-C and a-SMA positive spindle
shaped cells in bronchial mucosal biopsies as measures
of remodeling of large airways in patients with COPD.
We found that COPD patients had more expression of
both Tn-C and a-SMA positive cells compared to con-
trols. In addition, there was a positive correlation
between Tn-C and a-SMA expression. There were,
however, no correlations between the expression of Tn-
Co ra-SMA and any lung function parameter.
Due to the differential immunohistochemical expres-
sion of Tn-C and a-SMA we evaluated them in two dif-
ferent ways: Because the expression of Tn-C was mainly
extracellular and exhibited considerable variations
between individual patients, its expression was analyzed
by an applied semiquantitative method which took into
consideration the specific cellular and histopathological
localizations of the protein also in the areas around
basement membranes. In contrast, a-SMA expression
was mainly intracellular also in those spindle shaped
cells which were quantitatively counted in the present
study. Both these evaluation methods are easily applied
in routine clinical diagnostics since no extra equipments
is needed. For further development of our grading sys-
tems the use of computer-assisted tomography might be
beneficial. Our method has not been widely used and its
repeatability may be lesser than 3-dimensional or 2-
dimensional methods described previously [39].
Tn-C is a glycoprotein associated with tissue remodel-
ing. In a study by Liesker et.al.[ 1 5 ] ,a ni n c r e a s ei nT n -
C expression in the large airways was seen both in
COPD and in asthma patients. There was, however, no
difference between COPD patients and a matched ex-
smokers control group. There are several differences
between the study by Liesker et.al. and the present
study. Firstly, our study has two control groups: smokers
and non-smokers. Since there were no differences in
Tn-C expression between smokers and non smokers in
our study, we believe that the increased expression seen
in the COPD group is associated with the disease, i.e.
airways obstruction rather than exposure to tobacco
smoke. Secondly, in our study, quantitatively more
patients with a longer duration of smoking were investi-
gated, and the COPD patients had a more severe airway
obstruction. Finally, in our study all COPD patients
except three were current smokers, and all subjects in
the smokers control group were present smokers.
A previous study by Laitinen et.al.showed an increased
expression of Tn-C in the subepithelial layer of the
basement membrane of patients with asthma when
using immunofluorescence and morphometric methods
for analyzing the bronchial biopsy samples [17]. The
quantification method of Tn-C in the present study was
not similar to the study of Laitinen et.al. Since we ana-
lyzed the immunohistochemical expression of Tn-C in
the specific histological localizations of the airway
mucosa instead of measuring it. Furthermore, we
Figure 2 Number and proportion of subjects expressing Tenascin C outside the basal epithelial cells and basement membrane. Data is
given for the three groups COPD, smoking controls (S) and non-smoking controls (NS). Tn C (b+c): All subjects with expression outside the basal
epithelial cells and basement membrane. Tn C
©: Subjects with expression within connective tissue beyond the stroma underneath basal
membrane. The number (n) of individuals in each category is presented underneath corresponding bar. The Odds ratio for a COPD patient to be
in a higher category is statistically increased (P < 0.001) compared to subjects in the control groups.
Löfdahl et al. Respiratory Research 2011, 12:48
http://respiratory-research.com/content/12/1/48
Page 6 of 11Figure 3 The immunohistochemical expression of a-SMA, desmin and vimentin in bronchial biopsies from study subjects. The figures
show representative microphotographs from each category. A: High power field of spindle shaped cells positive for a-SMA; scale bar = 0.05
mm. B: High power field of desmin positive spindle shaped cells; scale bar = 0.05 mm. C: Ring like structures of blood vessels positive for a-SMA;
scale bar = 0.05 mm. D: Thick bundles of smooth muscle of the bronchial wall, staining for desmin; scale bar = 0.05 mm. E: Staining for vimentin
from a case in which no a-SMA or desmin positive spindle shaped cells were found. Positive staining pattern in normal fibroblasts and
lymphocytes of the subepithelial connective tissue; scale bar = 0.05 mm. F: A Negative control in which the primary antibody has been
substituted with non-immune mouse serum; scale bar = 0.1 mm.
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lial cells and basement membrane was higher in COPD
patients compared to that of smokers and nonsmokers.
The results of our study are somewhat similar to that
particular study in that respect that in both studies the
increase of Tn-C seemed to be correlated with the
remodeling process of the airways, and not to its trigger.
To our knowledge, not much attention has previously
been paid on Tn-C expression outside the basement
membrane area. We observed, however, that over 50%
of our COPD-patients showed an increased expression
of Tn-C beyond the basement membrane area. Laitinen
and co-workers analyzed also the number of eosinophils
and lymphocytes, but did not found any correlation
between the amount of these inflammatory cells and the
expression of Tn-C. In the present study we attempted
to compare the number of a-SMA positive spindle
shaped cells, which were obviously myofibroblasts, with
the amount of Tn-C and found a positive correlation
between these two markers.
Figure 4 Number and proportions of subjects with cells staining positive for a-SMA. Data is given for the three groups COPD, smoking
controls (S) and non-smoking controls (NS). The numbers (n) of individuals in each category is presented as digits underneath each bar. The
odds for a COPD patient to be in a higher category is statistically increased (P < 0.05) compared to subjects in the control groups.
Figure 5 Correlation between staining for Tenascin C and a-SMA in all subjects. Increasing degree of staining is indicated by categories a-
c and a-d. Number in the circles indicate number of subjects. The estimate for the correlation coefficient was 0.6; P < 0.0001.
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subject displayed a positive immunohistochemical
expression for Tn-C at least around basal cells of the
bronchial epithelium, a somewhat novel finding since
Tn-C has not regularly been shown to be expressed in
normal adult lung tissue. The results of our study might
signify that there is some constitutional expression of
Tn-C in basal epithelial cells of the human bronchus. In
our previous studies in normal developing human lung
the expressions of Tn-C protein and mRNA were
increased during early developmental stages, and
decreasing in the end of gestation [23]. In the normal
adult human lung Tn-C expression was observed to be
very sparse [40], although in our earlier studies we
focused mainly on the alveolar level, not the central air-
ways. However, the enhanced Tn-C expression, co-loca-
lized with the expression of myofibroblasts, has been
observed in small airways i.e. bronchioles of human
lung in neonatal disorders such as respiratory distress
syndrome (RDS) and bronchopulmonary dysplasia
(BPD) [37].
Both in pulmonary fibrosis and during lung develop-
ment a-SMA positive spindle shaped cells, which were
obviously myofibroblasts, seemed to be the main source
of mRNA of Tn-C by in situ hybridization method
[22,23,37]. Myofibroblasts were initially defined in ultra-
structural terms, with the essential features of intracellu-
lar fibers, which are positive for a-SMA, which is
nowadays the most common, yet not specific, marker
for a myofibroblast [24,41]. The origin of myofibroblasts
is still unclear. In our earlier studies human lung fibro-
blasts were differentiated into myofibroblasts by expos-
ing cells to transforming growth factor beta (TGF-b).
We observed that ultrastructural features of myofibro-
blasts were detected after exposure, e.g. a-SMA positive
bundles in the cytoplasm of cells, extracellular fibronec-
tin-containing structures on the surface of the cell, and
extracellular Tn-C in the vicinity of the cell [38]. Myofi-
broblasts seemed to have a role of the remodelling pro-
cess of airways in asthmatic lung at least in animal and
experimental models [42,43], but not much is currently
known about the expression profile and function of
myofibroblasts in COPD. Too u rk n o w l e d g et h i si st h e
first study showing that a-SMA positive cells, which
might be myofibroblasts, are increased in the airways of
the patients with COPD, and moreover, the number of
myofibroblasts correlated with the amount of Tn-C. The
results suggest that most a-SMA positive cells revealed
typical expression profile of myofibroblast being positive
for a-SMA, vimentin and negative for desmin. In the
minority of cases the a-SMA positive cells were positive
also for desmin, which may suggest the other known
phenotype for myofibroblast [25]. Interestingly, a-SMA
positive cells were not present in every patient, whereas
Tn-C positivity, at least in basal epithelial cells, was
observed in every patient studied, which may indicate
that the basal cells might be able to produce Tn-C in
large airways even in healthy lung, and that myofibro-
blasts may be responsible for the production of the
excess of Tn-C in patients with COPD.
The clinical relevance of our finding can only be
speculated. Hypothetically, increased ECM deposition
in the large airways in our COPD patients may contri-
bute to airways obstruction. It is, however believed
that the major site of airways obstruction in COPD is
in the small airways and increased airway wall thick-
ness has been shown to correlate with FEV1 [9,44]. It
is therefore likely to believe that the COPD patients in
t h ep r e s e n ts t u d ya l s oh a v ef e a t u r e so fr e m o d e l i n gi n
the small airways and probably also emphysema. Stu-
dies evaluating both large and small airways in a well
characterized patient material should therefore be
encouraged.
In conclusion, patients with COPD, but not smokers,
have signs of airway remodelling in the large airways as
measured as an increased expression of Tn-C and a-
SMA positive cells which were obviously myofibroblasts.
The finding may represent processes leading to struc-
tural changes in the airway wall causing lung function
impairment in COPD.
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